Ocugen Inc (OCGN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.36+0.74%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · OCGN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 557.6% |
| Our one-year growth estimate | diamond | -21.3% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 578.9 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is on a run of consecutive earnings misses and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
OCGN — earnings miss
Dated 2026-08-06
Results of Operations and Financial Condition. On August 6, 2026, Ocugen, Inc (the “Company”) issued a press release announcing certain financial results for the quarter ended June 30, 2026. The Company has scheduled a conference call and webcast for 8:30 a.m. Eastern Time on August 6, 2026, to discuss these financial results and business updates. The Company will use presentation materials in connection with the conference call and webcast, which presentation materials will be posted on the…
Why it matters: A new CFO can change how the company reports its finances. This could affect investor confidence.
Watch forThe next earnings report shows clearer and more accurate financial numbers.
Also watch forThe next earnings report shows problems or confusion in financial numbers.
Why it matters: This agreement could help Ocugen reach more markets and earn more money in the MENA region.
Supportive ifThe agreement for OCU400 licensing will be signed within 90 days.
Worry ifThe agreement is not signed, or terms change unfavorably.
Why it matters: Better cash flow is important for Ocugen's finances. It helps the company keep running.
Worry ifOperating losses will drop a lot in the next quarter.
Less concerning ifOperating losses go up or cash flow stays negative.
Why it matters: This submission is a key milestone for Ocugen's growth and could lead to market approval. Delays could hinder the company's plans.
Supportive ifBLA submission is officially filed with the FDA.
Worry ifSubmission is delayed beyond mid-2027 or not filed at all.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$228 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $707 loss on $10,000 · 7.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,242 loss on $10,000 · 52.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Sector growth trends can affect Ocugen's performance. Slowing growth may signal challenges ahead.
Worry ifSector revenue growth speeds up and moves closer to past highs.
Less concerning ifSector revenue growth slows down or stays the same.
Why it matters: Results will show how well OCU410ST works for Stargardt disease. Good results may speed up approval.
Supportive ifThe interim analysis shows a large drop in lesion size for treated patients.
Worry ifInterim analysis shows no big change in lesion size compared to controls.
Why it matters: Earnings results will show how well the company is performing. This can impact stock sentiment.
Watch forQ2 earnings show revenue growth or reduced losses compared to Q1.
Also watch forQ2 earnings report shows continued losses or revenue decline.
Why it matters: The $115M in convertible notes could affect financial stability. Investors will look for signs of effective use.
Supportive ifManagement has a clear plan to use the $115M well.
Worry ifNo clear plan or poor use of the $115M is communicated.
Why it matters: These results will show how well Ocugen's gene therapies work. Good data could help investors feel more confident.
Watch forTop-line results for OCU400 and OCU410ST trials are announced as expected in Q1 and Q2 2027.
Also watch forResults are late or show bad outcomes.
Why it matters: The $115M notes issuance affects capital allocation. This is important for financial health.
Watch forManagement says the $115M notes issuance helps them use their money better.
Also watch forManagement says there are challenges from the notes issuance.
Why it matters: Continued high losses signal trouble in managing cash flow. Investors watch for improvement.
Worry ifQ2 operating losses reported worse than -$17.8M.
Less concerning ifQ2 operating losses were better than -$17.8M.
Why it matters: Starting this trial is key for Ocugen's growth strategy. It shows progress in their late-stage programs.
Supportive ifThe OCU410 Phase 3 trial is initiated as planned in Q3 2026.
Worry ifThe OCU410 Phase 3 trial is delayed or not initiated as planned.
Why it matters: Top results will show how well OCU400 works for retinitis pigmentosa. This is key for future approvals.
Supportive ifTopline results from the OCU400 Phase 3 trial are announced in Q1 2027.
Worry ifTopline results from the OCU400 Phase 3 trial are not released as scheduled.
Why it matters: Finishing this agreement would help Ocugen reach more markets in the MENA region. This could increase revenue.
Supportive ifA final deal with Roots Pharmaceutical will be signed in 90 days.
Worry ifThe final agreement with Roots Pharmaceutical is not signed on time.
Why it matters: This analysis will give early signs of how well OCU410ST works for Stargardt disease.
Watch forThe interim results of the OCU410ST trial show positive signs.
Also watch forThe interim results of the OCU410ST trial show negative signs.